Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)
MP4•Episode home
Manage episode 477271709 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics:
- Overview of the current JAK inhibitor landscape (0:00)
- Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02)
- Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17)
- Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13)
- Available clinical data with novel BET inhibitors (15:00)
- Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50)
- Emerging efficacy and safety findings reported with imetelstat for MF (18:57)
- Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15)
- Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05)
- Other novel agents and strategies under investigation for MF (26:06)
1555 episodes
MP4•Episode home
Manage episode 477271709 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics:
- Overview of the current JAK inhibitor landscape (0:00)
- Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02)
- Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17)
- Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13)
- Available clinical data with novel BET inhibitors (15:00)
- Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50)
- Emerging efficacy and safety findings reported with imetelstat for MF (18:57)
- Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15)
- Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05)
- Other novel agents and strategies under investigation for MF (26:06)
1555 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.